NAFLD1
MCID: FTT008
MIFTS: 30

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1) malady

Categories: Liver diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

Aliases & Descriptions for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 54 29
Hepatic Steatosis 66 29
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 13
Non-Alcoholic Fatty Liver Disease 1 66
Steatohepatitis 69
Fatty Liver 69
Nafld1 66

Characteristics:

HPO:

32
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 54 613282
MeSH 42 D005234

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 54 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is... (613282) more...

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules and lipodystrophy, familial partial, 2, and has symptoms including hepatic steatosis An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is NAFLD1 (Fatty Liver Disease 1, Susceptiblity To). The drugs Metformin and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver.

UniProtKB/Swiss-Prot : 66 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.0
2 lipodystrophy, familial partial, 2 11.5
3 hypobetalipoproteinemia 11.3
4 nonalcoholic steatohepatitis 11.2
5 lipodystrophy, congenital generalized, type 3 11.0
6 lipodystrophy, congenital generalized, type 2 11.0
7 visceral steatosis 11.0
8 lipodystrophy, familial partial, type 5 10.9
9 abetalipoproteinemia 10.9
10 citrullinemia, adult-onset type ii 10.9
11 lipodystrophy, congenital generalized, type 1 10.9
12 neutral lipid storage disease with myopathy 10.9
13 combined oxidative phosphorylation deficiency 21 10.9
14 lipodystrophy, congenital generalized, type 4 10.9
15 combined oxidative phosphorylation deficiency 16 10.9
16 lipodystrophy, familial partial, type 6 10.9
17 hepatitis 10.8
18 obesity 10.4
19 hepatitis c 10.3
20 fatty liver disease 10.1
21 liver disease 10.1
22 hypertriglyceridemia 10.1
23 glucose intolerance 10.1
24 hepatitis b 10.0
25 lipodystrophy 10.0
26 hepatitis c virus 10.0
27 insulinoma 9.9
28 polycystic ovary syndrome 9.9
29 alcoholic hepatitis 9.9
30 viral hepatitis 9.9
31 influenza 9.8
32 arthritis 9.8
33 cholestasis 9.8
34 psoriatic arthritis 9.8
35 intrahepatic cholestasis 9.8
36 metastatic insulinoma 9.8
37 lactic acidosis 9.8
38 hepatocellular carcinoma 9.8
39 hyperglycemia 9.8
40 microsporidiosis 9.8
41 pancreatitis 9.8
42 hemochromatosis 9.8
43 alcohol abuse 9.6
44 portal hypertension 9.6
45 hyperandrogenism 9.6
46 homocystinuria 9.6
47 glucocorticoid resistance 9.6
48 atherosclerosis 9.6
49 reye syndrome 9.6
50 hyperhomocysteinemia 9.6

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Symptoms by clinical synopsis from OMIM:

613282

Clinical features from OMIM:

613282

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

32
id Description HPO Frequency HPO Source Accession
1 hepatic steatosis 32 HP:0001397

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
7
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
8
Ribavirin Approved Phase 4 36791-04-5 37542
9
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
10
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
11
Insulin Aspart Approved Phase 4 116094-23-6 16132418
12
Insulin Detemir Approved Phase 4 169148-63-4 5311023
13
Selenium Approved, Vet_approved Phase 4 7782-49-2
14
Gliclazide Approved Phase 4 21187-98-4 3475
15
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
16
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
17
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
18
Ethanol Approved Phase 4,Phase 3 64-17-5 702
19
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
20
Glimepiride Approved Phase 4 93479-97-1 3476
21
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
22
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
23
Empagliflozin Approved Phase 4 864070-44-0
24
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-02-9 14985
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
26
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
27
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
28 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30
Angiotensin II Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7 65143 172198
31 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
32 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
33 Angiotensinogen Phase 4,Phase 3,Phase 2
34 Antihypertensive Agents Phase 4,Phase 3,Phase 2
35 diuretics Phase 4,Phase 2
36 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Natriuretic Agents Phase 4,Phase 2
39 Sodium Chloride Symporter Inhibitors Phase 4
40 Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
41 Hormones Phase 4,Phase 2,Phase 3,Early Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
43 Micronutrients Phase 4,Phase 3,Phase 2
44 Tocopherols Phase 4,Phase 3,Phase 1,Phase 2
45 Tocotrienols Phase 4,Phase 3,Phase 1,Phase 2
46 Trace Elements Phase 4,Phase 3,Phase 2
47 Vitamins Phase 4,Phase 3,Phase 1,Phase 2
48 Anti-Infective Agents Phase 4,Phase 3,Phase 2
49 Antimetabolites Phase 4,Phase 2,Early Phase 1
50 Antiviral Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 283)
id Name Status NCT ID Phase
1 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
2 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
3 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
4 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4
5 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4
6 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4
7 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4
8 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4
9 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4
10 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4
11 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4
12 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4
13 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4
14 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Recruiting NCT02147925 Phase 4
15 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4
16 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4
17 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4
18 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Recruiting NCT02213224 Phase 4
19 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4
20 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Recruiting NCT02721888 Phase 4
21 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4
22 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4
23 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Not yet recruiting NCT02984475 Phase 4
24 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4
25 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4
26 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
27 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3
28 Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease Unknown status NCT02303314 Phase 2, Phase 3
29 A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Unknown status NCT02265276 Phase 3
30 Targeting Inflammation Using Salsalate in CardioVascular Disease Unknown status NCT00624923 Phase 2, Phase 3
31 Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis Completed NCT02068339 Phase 3
32 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3
33 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
34 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3
35 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3
36 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3
37 Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes Completed NCT02132442 Phase 3
38 Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children Completed NCT01529268 Phase 2, Phase 3
39 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
40 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3
41 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3
42 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Recruiting NCT02541045 Phase 3
43 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Recruiting NCT02654665 Phase 3
44 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3
45 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT02704403 Phase 3
46 Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Recruiting NCT03053063 Phase 3
47 Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Recruiting NCT03053050 Phase 3
48 AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH Recruiting NCT03028740 Phase 3
49 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Recruiting NCT02649335 Phase 3
50 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Active, not recruiting NCT02279524 Phase 2, Phase 3

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

id Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

39
Liver

Publications for Fatty Liver Disease, Nonalcoholic 1

Variations for Fatty Liver Disease, Nonalcoholic 1

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....